Completed PHASE3 INTERVENTIONAL NCT00080457

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hypertension (PAH)

Sponsor: Encysive Pharmaceuticals

Conditions Pulmonary Hypertension

Interventions sitaxsentan sodium

Updated 5 times since 2017 Last updated: Nov 8, 2007 Started: May 31, 2003 Completion: Jan 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Pulmonary Hypertension and is currently completed. Encysive Pharmaceuticals leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Encysive Pharmaceuticals

Data source: Encysive Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States